Brocard, Simon https://orcid.org/0009-0006-4327-7773
Morin, Martin
dos Santos Brito Silva, Nayane
Renaud-Picard, Benjamin
Coiffard, Benjamin
Demant, Xavier https://orcid.org/0000-0003-0045-2018
Falque, Loïc
Le Pavec, Jérome
Roux, Antoine
Villeneuve, Thomas
Knoop, Christiane
Mornex, Jean-François
Salpin, Mathilde
Boussaud, Véronique
Rousseau, Olivia https://orcid.org/0000-0002-5726-9620
Mauduit, Vincent https://orcid.org/0000-0001-7352-8162
Durand, Axelle https://orcid.org/0000-0002-4291-2281
Magnan, Antoine
Gourraud, Pierre-Antoine
Vince, Nicolas https://orcid.org/0000-0002-3767-6210
Südholt, Mario
Tissot, Adrien
Limou, Sophie https://orcid.org/0000-0002-7702-8234
,
Le Pavec, Jérome
Funding for this research was provided by:
S. Brocard benefits from the support of IMT Atlantique, Centrale Nantes and Institut de Recherche en Santé Respiratoire des Pays de la Loire for his PhD research.
Article History
Received: 29 February 2024
Revised: 29 July 2024
Accepted: 6 August 2024
First Online: 20 August 2024
Competing interests
: PA Gourraud is the founder of Methodomics (2008) and a co-founder of Big data Santé (2018). He consults for major pharmaceutical companies, and start-ups, all of which are handled through academic pipelines (AstraZeneca, Biogen, Boston Scientific, Cook, Docaposte, Edimark, Ellipses, Elsevier, Janssen, Lek, Methodomics, Merck, Mérieux, Octopize, Sanofi-Genzyme). PA Gourraud is a volunteer board member at AXA not-for-profit mutual insurance company (2021). He has no prescription activity with either drugs or devices. The other authors declare no conflicts of interest.
: This study protocol was approved by ethics committee (<i>Comité de Protection des Personnes</i>, 2009-A00036-51) the study and all participants provided a written informed consent (CNIL French data protection authority, #911142).